LAVA THERAPEUTICS NV (LVTX) Stock News

NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD

1.52 +0.09 (+6.29%)

After market: 1.47 -0.05 (-3.29%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LVTX Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: LAVA Therapeutics N.V.

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

3 months ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

4 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

5 months ago - By: Benzinga - Mentions: JNJ PFE

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

5 months ago - By: Benzinga - Mentions: OLN SRE STZ FLYW

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

a year ago - By: BusinessInsider

News Image

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

a year ago - By: BusinessInsider

News Image

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

7 months ago - By: LAVA Therapeutics N.V.

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

8 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

a year ago - By: BusinessInsider

News Image

LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2024 Financial Results and Business Update

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

a year ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA OCEA MRK ...

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

2 years ago - By: InvestorPlace - Mentions: ACON HSHP EKSO PBLA ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday